Mammalian DPPIII exhibits particular affinity for the degradation of hypertension-inducing peptides via the inactivation and degradation of angiotensin II to angiotensin III; the consequential reduction in vasoconstrictor activity likely induces hypotension alongside thrombolysis, by reducing the activity of plasminogen activator inhibitors that constrain fibrinolysis [68-70]. Here, DPP3 is linked to hypertensive disorder.